By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...
Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after ...
SurvivorNet on MSN
ASCO 2026: A major prostate cancer trial shows drug can keep high-risk disease from returning for longer
Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...
The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...
Johnson & Johnson said its prostate cancer drug Erleada, when used with hormone-blocking therapy before and after prostate ...
MedPage Today on MSN
Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy
ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...
Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...
Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...
Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results